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Abstract: T lymphocytes expressing the CLA antigen constitute a
subset of effector memory lymphocytes that are functionally
involved in T-cell-mediated cutaneous diseases. Skin-seeking
lymphocytes recirculate between inflamed skin and blood during
cutaneous inflammation. Many studies in different T-cell-
mediated inflammatory cutaneous diseases have clearly related
their pathologic mechanisms to CLA+ T cells. Based on common
features of these cells in different cutaneous disorders mediated by
T cells, we propose that circulating CLA+T cells could constitute
very useful peripheral cellular biomarkers for T-cell-mediated skin
diseases.
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Introduction
Most of the cytokine producing T cells during cutaneous inflamma-
tion belong to the memory phenotype (1). Memory T lymphocytes
present in the circulation are not distributed randomly to periph-
eral tissues (2). Specific mechanisms guide those cells to cutaneous
locations under homoeostatic conditions in inflammation, infec-
tions and cancer. The cutaneous lymphocyte-associated antigen
(CLA) is a cell-surface carbohydrate induced by the fucosyltransfer-
ase VII-dependent post-translational modification of platelet
(P)-selectin glycoprotein ligand 1 (PSGL-1) and interacts with
endothelial (E)-selectin. CLA distinguishes human effector memory
CD45R0+ T cells (3,4) with cutaneous tropism involved in patho-
logic mechanisms of T-cell-mediated skin diseases (5). CLA+ T cells
are present in approximately 15% to 20% of CD3+ cells (6), and
most infiltrating T cells in cutaneous lesions are CLA+, whereas T
cells infiltrating non-cutaneous tissues are CLA (3). Healthy skin
also harbours CLA+ T cells (7).
The CLA antigen is part of a complex multistep molecular
interaction between circulating lymphocytes and cutaneous vascu-
lar endothelium that takes place during lymphocyte migration to
the skin. Proinflammatory mediators expressed under inflamma-
tory conditions, like IL-1 or TNF-a, upregulate the expression of
adhesion molecules and chemokines on the surface of endothelial
cells (5).
Some studies have shown numerical and phenotypical changes
in circulating CLA+ T cells that are related to cutaneous disease
severity and clinical evolution in T-cell-mediated skin diseases
(5,8). However, in such cases, CLA+ T-cell recirculation between
affected skin and blood during cutaneous inflammation has not
been fully demonstrated in humans. As mentioned, beside other
adhesion molecules and chemokines, CLA+ T cells require the
LFA-1/ICAM-1 interaction during their transendothelial migration
in vitro (9,10). Information regarding the mode of action of
anti-LFA-1 treatments has been obtained from clinical trials in
psoriasis and atopic dermatitis (11–13), providing translational
evidence in favour of effector memory CLA+ T-cell recirculating
capacity between skin and blood during cutaneous inflammation.
If continuous recirculation occurs between inflamed skin and
blood during cutaneous inflammation in psoriasis and atopic
dermatitis, blockade of extravasation of T cells from blood into
skin with anti-LFA-1 treatment should affect normal circulating
levels of CLA+ T cells. In fact, in both diseases, a rise in circulat-
ing CLA+ T cells is observed in parallel to the clinical improve-
ment of inflammation due to treatment (12,13).
Such clinical phenomena might be explained by two mecha-
nisms. First, the LFA–1/ICAM-1 interaction is involved in the
transendothelial migration of CLA+ T cells; second, infiltrating
CLA+ T cells recirculate from the lesion to the blood through the
thoracic duct and accumulate in the blood (Fig. 1a). Skin-
activated CLA+ T cells that recirculate to blood could not extrava-
sate due to the blockade of their adhesion mechanisms and they
would accumulate, inducing CLA+ T-cell lymphocytosis (Fig. 1b).
Such lymphocytosis present during treatment with anti-LFA-1 can
have clinical relevance: a skin relapse may develop after stopping
the treatment (11). A similar phenomenon has been observed for
a different memory T-cell subset when blocking the alpha4 inte-
grin in multiple sclerosis, leading to lymphocytosis (14).
T-cell skin-homing mechanisms have been extensively studied
in the mouse and recently reviewed (15). However, the study of
those cells in patients with chronic cutaneous inflammatory
diseases is a more complex situation. Understanding immunologi-
cal mechanisms responsible for skin flares in patients with long-
standing atopic dermatitis, or psoriasis, is different from those
induced de novo by delayed-type hypersensitivity in a sensitized
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mouse to haptens or antigens. The chronicity and maintenance
of those T-cell-mediated diseases can reside on antigen-specific
memory T cells present in blood and involved in the skin flares
during cutaneous effector phases. For example, in patients with
atopic dermatitis or contact dermatitis, circulating effector
memory CLA+ T cells, but not CLA, respond to house dust
mites or nickel, suggesting a compartmentalization of the immune
response present in periphery (16).
Analysis of the peripheral blood CLA+ T-cell populations pro-
vides opportunity to better understand human T-cell-mediated
skin diseases. Circulating CLA+ T cells have recirculating capac-
ity, show specificity towards cutaneous antigens/allergens/autoan-
tigens, and their phenotype is influenced by the cutaneous
environment to which they have been exposed. Our point of
view is that there are evidences from different cutaneous diseases
that support the relevance of circulating CLA+ T cells as cellular
peripheral biomarkers and as a source of translational knowledge
in T-cell-mediated skin diseases.
Psoriasis
CLA+ T cells are considered key cellular elements in the mecha-
nism involved in psoriasis lesion formation (17–20). They are
present at the initial stage of plaque psoriasis before epidermal
hyperplasia takes place (21,22). The percentage of CLA+ T cells in
peripheral blood correlates inversely with Psoriasis Area and
Severity Index (PASI) and body surface area (BSA) in acute but
not in chronic psoriasis (23), suggesting a sequestration of those
cells from blood into inflamed skin. In addition, the number of
circulating CD4 + CLA + and CD3 + CLA + cells expressing the
activation marker HLA-DR is increased in peripheral blood of
psoriatic patients with active disease compared to patients with
chronic lesions (24). Recently, a novel subset of human skin-hom-
ing CLA + CCR6 + Vc9Vd2 T cells has been identified (25). As in
previous studies, the number of circulating CLA + Vc9Vd2 T cells
correlated inversely with PASI score and increased with successful
treatment.
In psoriasis, CLA+ T cells not only migrate to skin but partici-
pate in the initiation of lesion. It has been suggested that CLA+ T
cells are present in non-lesional psoriatic skin before epidermal
hyperplasia takes place (21). Some infections have been described
as relevant triggers of psoriasis, especially Streptococcus pyogenes
(18,26) or cytomegalovirus (27). Streptococcal tonsillar infection
can induce the onset of the disease or trigger relapses (26). CLA+
T cells are generated, upon activation by Streptococcus pyogenes
superantigens, in tonsils and migrate to psoriatic cutaneous
lesions. In fact, an identical and highly restricted TCR usage has
been found in CLA+ T cells present in tonsils and psoriatic lesion
express of the same patient, suggesting migration of those cells
from tonsil to skin lesion (28). Circulating CLA + CD8 + T cells
react with keratin peptides that share sequence with streptococcal
M proteins (29) and their percentage in peripheral blood corre-
lates with disease severity (30). Interestingly, in psoriatic patients
with a previous history of exacerbation after sore throat, a close
correlation has been recently demonstrated between the degree of
clinical improvement after tonsillectomy and the reduction in the
frequency of circulating CLA + CD8 + lymphocytes specific to
peptides shared by streptococcal M proteins and skin keratins
(31). The relevance of streptococcal throat infection has been
known for more than 50 years (32); recently, it has been demon-
strated that psoriatic circulating effector memory CLA+ T, but not
CLAnegative, upon activation with streptococcal extract secrete
Th1/Th17 cytokines and induce keratinocyte activation an
hyperplasia (33).
All these studies underline the relevance of studying circulating
CLA+ T cells in psoriasis because they are related to pathologic
mechanisms in this chronic cutaneous inflammation. This is not
surprising because psoriatic lesions produce a great variety of
chemokines that can attract circulating CLA+ T cells to cutaneous
psoriatic lesions such as CCL20, CCL27, CXCL8, CXCL9,
CXCL10, CXCL11 (34) and CXCL16 (35). Several studies have
demonstrated that the amount of circulating CLA+ T cells is
altered during effective antipsoriatic treatments (25,31,36). It has
been shown in a murine psoriasis model that therapeutic doses of
PUVA resulted in a sequestration of CLA + CD25 + CD4 +
T cells in lymph nodes, suggesting the migration from peripheral
nodes to skin (and vice-versa), where they would induce PUVA
therapeutic effect (37). In humans, changes of CLA expression in
the periphery have been found to correlate with long-term clinical
responsiveness to synchronous balneophototherapy using narrow
band UVB light (38). Similarly, regarding TNF-alpha inhibitor
biological therapy, a significant difference has been recently found
between peripheral CLA expression tendencies of responder and
relapsing patients in the induction treatment period (39). These
results highlight a potential predictive importance of the CLA
molecule in different psoriasis therapies.
Other cutaneous inflammatory diseases
Several studies have reported that, in different T-cell-mediated
cutaneous diseases, the clinical status can induce changes in phe-
notype, cell numbers or related mechanisms of CLA+ T cells. In
atopic dermatitis, circulating CLA+ T cells recognize allergens or
bacterial molecules involved in the pathogenesis of eczema devel-
opment. Their role in atopic dermatitis and other allergic diseases
has been recently reviewed (8,40). Circulating CLA+ T cells are
attracted into cutaneous lesions by different chemokines, whose
specific receptors are present on the CLA+ T-cell surface. Serum
levels of CCL17, CCL22 and CCL27 have been correlated with the
clinical severity of atopic dermatitis. Circulating CLA+ T cells
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Figure 1. Circulating CLA+ T cells as cellular biomarkers. CLA+ T cells recirculate
between blood and skin (a) through specific adhesion and chemotactic
mechanisms. Anti-LFA-1 blocking antibodies inhibit the migration of CLA+ T cells
from blood into skin and cause accumulation of lesion-derived CLA+ T cells in
blood (b). Studying peripheral CLA+ T cells allows obtaining information about
immune-inflammatory processes taking place in the skin.
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from patients with active atopic dermatitis express T-cell activa-
tion markers and spontaneously produce IL-4 (16) and IL-13
(41), as expected for a lymphocyte population that recirculates
between inflamed skin and blood.
Neuropeptides are thought to influence the mechanism of cuta-
neous flares in atopic dermatitis, and stress is a well-known trigger
of disease flares. A recent study has demonstrated how calcitonin
gene-related peptide, but not other neuropeptides, selectively acti-
vates circulating CLA+ T cells from atopic dermatitis patients,
inducing IL-13 production in a manner independent of T-cell
receptors (42). Considering that CLA+ T cells preferentially pro-
duce IL-31, an important cytokine involved in pruritus generation
(43), circulating skin-homing T cells can also be of value as cellu-
lar biomarkers of molecular processes involved in T-cell-mediated
pruritus.
In non-immediate cutaneous reactions to drugs such as
beta-lactams and anticonvulsants, CLA+ T cells are the subset of
memory T cells that respond to those antigens (44). Under
re-exposure, those cells express activation markers in parallel to
the cutaneous symptoms (45). The CLA antigen is also expressed
on the surface of regulatory T cells (T-regs) implicated in the pre-
vention of acute graft-versus-host disease (aGVHD) after alloge-
neic stem cell transplantation (ASCT). Increased amount of CLA+
T-regs at engraftment is associated with the prevention of skin
aGVHD (46). A threshold value for CLA+ T-regs could be of
use to predict important hematopoietic cell transplant (HCT) out-
comes and may help to direct the rational use of tissue-specific
preventive therapies to decrease clinical aGVHD and improve
HCT survival (47). In scleroderma, a new venue of research has
been initiated by studying circulating CD8 + CLA+ T cells in early
stages of the disease. Those cells produce IL-13, accumulate in the
lesions and produce cytotoxic granules that may be involved in
the early vascular damage present in scleroderma (48).
Skin tumors
CLA+ T lymphocytes homing to cutaneous lesions play a central
role in anti-tumoral immune responses (49). Although the hetero-
geneous subset of tumor-infiltrating lymphocytes (TILs) in malig-
nant melanoma involves cells with both tumor-stimulating and
tumor-inhibiting properties (50), a common feature of these cells
is CLA expression (51) accompanied by special combinations of
chemokine receptors (52,53). In metastatic lesions, endothelial cell
adhesion molecule expression (e.g. E-selectin, the pair of the CLA
antigen) markedly declines, which explains decreased skin- and
tumor-infiltrating capacity of circulating CLA+ reactive lympho-
cytes as well as unimpeded tumor progression (54). Similarly, a
downregulation of endothelial adhesion molecules and the conse-
quent inhibition of CLA+ lymphocyte extravasation have been
reported in epithelial skin cancers (squamous cell carcinoma and
basal cell carcinoma) (55,56).
In primary cutaneous T-cell lymphomas, co-expression of CLA
and skin-specific chemokine receptors on T lymphocytes is a
requisite for T-cell skin infiltration (49). The distinct clinical
behaviour of mycosis fungoides (MF) and Sezary syndrome (SS)
might be explained by a different origin of the tumor cells. In
MF, the main skin addressins, CLA and chemokine receptor
CCR4 guide malignant effector memory T lymphocytes to the
skin. These cells typically lack lymph node homing receptors
(CCR7, L-selectin) explaining why tumor cells are primarily found
in the skin without circulating in the periphery and infiltrating
lymph nodes (57). However, in parallel with progression, tumor
cells downregulate skin-specific homing molecules, accumulate in
blood and express great amounts of lymph node–homing markers
(58). A variable degree of circulating tumor cell CLA expression
has been demonstrated in SS with general co-expression of lymph
node addressins, referring to the central memory phenotype of
malignant lymphocytes. A subset of these cells showing prominent
expression of CLA and CCR4 migrates to cutaneous areas (57). A
strong correlation has been observed between percentage of CLA+
circulating lymphoma cells and extent of skin symptoms (59,60).
These major differences in tumor cell–homing abilities may
explain why MF is confined to skin and has an overall better
prognosis than SS, with involvement of skin, peripheral circula-
tion, lymph nodes and a general poor clinical outcome (57).
All in all, tumor progression is facilitated by decreased expres-
sion of endothelial adhesion molecules in malignant tumors.
Enhancing migratory capacity of CLA+ reactive immune cells
could be beneficial in the therapy. Skin infiltration of CLA+ tumor
cells is a key feature of primary cutaneous T-cell lymphomas.
Targeted inhibition of tissue-specific tumor cell homing might be
of notable therapeutic importance in the future.
In summary, results obtained from different T-cell-mediated
skin diseases highlight the relevance of circulating CLA+ T cells.
These cells may be a source of information as peripheral cell
biomarkers, both in a predictive or retrospective way, as their
number and phenotype parallel local cutaneous events and corre-
late with clinical activity and treatments. In addition, the study of
different subsets of CLA+ T cells can bring added value in the
biomarker area such as those recently activated lymphocytes (24)
or expressing certain chemokine receptors on their surface. Future
clinical trials are required to validate the relevance of circulating
CLA+ T cells as clinical biomarkers for T-cell-mediated cutaneous
diseases.
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